- Home
- GHC vs VKTX Comparison
GHC vs VKTX Comparison
Compare GHC & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GHC | VKTX |
|---|---|---|
| Founded | 1877 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 3.4B |
| IPO Year | 1994 | 2014 |
Fundamental Metrics
Financial Performance| Metric | GHC | VKTX |
|---|---|---|
| Price | $1,045.91 | $33.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $88.00 |
| AVG Volume (30 Days) | 14.2K | ★ 2.9M |
| Earning Date | 05-28-2026 | 05-14-2026 |
| Dividend Yield | ★ 0.71% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 66.47 | N/A |
| Revenue | ★ $2,932,099,000.00 | N/A |
| Revenue This Year | $10.54 | N/A |
| Revenue Next Year | $4.02 | N/A |
| P/E Ratio | $15.76 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $875.60 | $18.92 |
| 52 Week High | $1,224.76 | $43.15 |
Technical Indicators
Market Signals| Indicator | GHC | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 36.03 | 57.54 |
| Support Level | $913.37 | $30.73 |
| Resistance Level | $1,115.27 | $35.66 |
| Average True Range (ATR) | 36.31 | 1.81 |
| MACD | -5.77 | 0.56 |
| Stochastic Oscillator | 20.05 | 75.48 |
Price Performance
Historical ComparisonAbout GHC Graham Holdings Company
Graham Holdings Co. is a diversified education and media company made up of subsidiaries. Firm operations include educational services; television broadcasting; online, print, and local news; home health and hospice care; and manufacturing. The Company segments into the following seven reportable segments: Kaplan International, Higher Education, Supplemental Education, Television Broadcasting, Manufacturing, Healthcare, and Automotive. The majority of revenue comes from the Kaplan International segment, which includes higher education, test preparation, language instruction, and professional training. A large portion of company revenue also comes from the television broadcasting segment through advertising.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.